TTK is a kinase with dual specificity, meaning it can phosphorylate both tyrosine and serine/threonine residues. The gene is involved in cell proliferation, which is required for chromosomal orientation at the centromere during mitosis and centrosome duplication. It was revealed to be an important mitotic checkpoint protein for proper chromosomal segregation during mitosis. They have a lot of potential as a therapeutic target for breast cancer, solid tumours, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, prostate cancer, and other cancers.
The worldwide dual specificity protein kinase TTK market is projected to develop due to rising pipeline compounds linked with dual specificity protein kinase TTK as an intended treatment for many cancer types. TTK, a dual specificity protein kinase, has a pipeline of over 10 to 12 compounds, with over 7 of them created by the business and the rest by universities/institutes.
Market segementation
By product type:
- BAY-1217389
- CCT-271850
- CFI-402257
- NMSP-153
- NMSP-715
- Others
By application:
- Solid Tumor
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Others
Protein kinase with a dual specificity The TTK gene codes for an enzyme called TTK. It's linked to cell proliferation, and it's necessary for centrosome duplication as well as chromosomal alignment at the centromere during mitosis. It serves as a crucial mitotic checkpoint protein, ensuring that chromosomes are correctly segregated during mitosis. Companies are currently developing 1, 2, and 5 compounds in Phase II, Phase I, and Preclinical phases. In the same way, the university's Phase II and Preclinical portfolios each have one and two compounds. The report includes items from the Oncology therapeutic categories, with indications such as Triple-Negative Breast Cancer (TNBC), Metastatic Breast Cancer, and Somatic Symptomatic Breast Cancer. Triple-Negative Breast Cancer (TNBC), Metastatic Breast Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer, and Hormone Refractory (Castration Resistant and Androgen-Independent).
The major players operating in the dual specificity protein kinase TTK market include Bayer AG, Boston Pharmaceuticals, Les Laboratoires Servier SAS, Nerviano Medical Sciences Srl, Netherlands Translational Research Center BV, and Pfizer Inc.
